8-K
filed May 28, 2026, 4:59 PM ET
ticker RLMD
CIK 0001553643
other
confidence high
sentiment neutral
materiality 0.35
Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment
RELMADA THERAPEUTICS, INC.
- Authorized shares increased from 150M to 200M via charter amendment filed May 28, 2026.
- Annual meeting held May 27: 63.5% of eligible shares voted; directors Casamento and Traversa elected.
- Stockholders ratified CBIZ CPAs P.C. as auditor for FY 2026.
- 2021 Equity Incentive Plan amended to increase available shares by 3M to 18,052,942 total.
- Proposals 1-4 all approved; no material dissent on auditor or charter amendment.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
RELMADA THERAPEUTICS, INC.: Increased authorized common shares from 150,000,000 to 200,000,000 (effective 2026-05-28).
- Change
- charter amendment
- Effective
- 2026-05-28
Exact text from the filing
On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “ Charter Amendment ”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RELMADA THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Auditors at the 2026-05-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Withheld Broker Non-Votes 66,097,327 104,854 369,530 -
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RELMADA THERAPEUTICS, INC. shareholders approved Approval of the Charter Amendment to increase authorized shares at the 2026-05-27 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 4: Approval of the Charter Amendment Stockholders approved the proposed amendment to the Company’s Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 150,000,000 to 200,000,000. The Charter Amendment is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026 For Against Withheld Broker Non-Votes 65,072,921 1,170,378 328,412 -
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RELMADA THERAPEUTICS, INC. shareholders approved Approval of an Amendment to the 2021 Plan at the 2026-05-27 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 3: Approval of an Amendment to the 2021 Plan. Stockholders approved the proposed amendment to the Company’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”), to increase the number of shares of the Company’s common stock available for issuance pursuant to awards under the 2021 Plan by 3,000,000 to an aggregate of 18,052,942 (including awards previously granted). The 2021 Plan is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026. For Against Withheld Broker Non-Votes 36,480,855 18,181,681 85,048 11,824,127
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
RELMADA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-05-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2029 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified or until his earlier resignation or removal. Nominee For Withheld Broker Non-Votes Charles J. Casamento (Class II, 36 month term) 33,859,106 20,888,478 11,824,127 Sergio Traversa (Class II, 36 month term) 54,124,764 622,820 11,824,127
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.